Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
105 people get LPDX articles and Market Currents by email alert.
Get email alerts on LPDX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (Tue, 7:30AM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 2, 2013)
-
Business Wire (Apr 25, 2013)
-
-
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 27, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
Business Wire (Mar 11, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
-
-
-
-
-
2 IPOs Scheduled For Week Of January 21stIPOdesktop • Tue, Jan 22
-
-
-
-
-
-
2 IPOs Scheduled For Week Of January 21stIPOdesktop • Tue, Jan 22
-
-
GlobeNewswire (Tue, 7:30AM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 2, 2013)
-
Business Wire (Apr 25, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 27, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
Business Wire (Mar 11, 2013)
-
GlobeNewswire (Mar 7, 2013)
LPDX vs. ETF Alternatives
Company Description
We are an in vitro diagnostic company pioneering a new field of personalized diagnostics based on nuclear magnetic resonance, or NMR, technology. Our first diagnostic test, the NMR LipoProfile test, directly measures the number of low density lipoprotein, or LDL, particles in a blood sample and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Friday, May 10, 12:52 PM
Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move] - Friday, May 10, 12:34 PM LipoScience (LPDX -22.8%) tanks after CEO Richard Brajer expresses his dissatisfaction with the company's revenue performance in Q1 (-1.2% Y/Y). LipoProfile test order growth fell to 8.7% Y/Y versus Y/Y growth of 14.8% in Q4, although orders did rise Q/Q. The main problems — which include difficulties ramping up new sales reps, faster direct business-to-lab partner conversion, and managed care headwinds — "cannot be fixed overnight," Brajer laments. In light of this, LPDX lowers its FY13 revenue guidance to $54-56M (consensus is $61.43M). (PR) Comment! [Healthcare, On the Move]
- Friday, May 10, 6:18 AM LipoScience (LPDX): Q1 EPS of -$0.19 misses by $0.01. Revenue of $13.6M misses by $0.55M. (PR) Comment! [Earnings, Breaking News]
- Wednesday, March 27, 4:31 PM LipoScience (LPDX): Q4 EPS of $0.13. Revenue of $13.6M (+8.6% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 19, 1:51 PM LipoScience (LPDX +0.6%) moves up after Piper Jaffray initiates the shares with an Overweight and a $15.00 price target. Piper notes that ongoing traction converting its LDL-C patient monitoring assays to LDL-P and represents a potential $330M annual revenue run-rate, which would exceed both its top and bottom-line projections. Separately, Barclay's and UBS also initiated coverage with an Overweight and Buy, respectively. Comment! [Healthcare, On the Move]
- Friday, January 25, 10:37 AM IPO LipoScience (LPDX) opens for trading this morning at $9.75 per share after pricing 5M shares at $9, the low end of its previously reduced $9 - $10 range. Comment! [Healthcare]
- Friday, January 25, 8:43 AM LipoScience (LPDX) cuts its IPO range to $9-10 from $13-15. At 5M shares, that will be about $48M raised for the medical diagnostic firm whose nuclear magnetic resonance (NMR) LipoProfile test provides risk assessment for cardiovascular events. Comment! [Healthcare]